In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2009

Executive Summary

Medical device financing--primarily made up of late venture rounds--totaled just over $1 billion in Q3 2009, a 19% increase over the previous quarter. Acquisition dollars in the industry also surpassed $1 billion and included two $400 million-deals by Abbott. Most of the third quarter financing into in vitro diagnostics and research/analytical came from Qiagen's $628 million FOPO. And Agilent's $1.5 billion purchase of bioanalytical instrument maker Varian was the highest-value takeover.
Advertisement

Related Content

Covidien Gains BIS Anesthesia Monitoring Technology In Aspect Medical Buy
Device Companies Look Far and Wide for New Capital
With DxS, Qiagen Moves into Personalized Medicine
Device Companies Look Far and Wide for New Capital
Abbott Moves into Heart Valves with Evalve Deal
With DxS, Qiagen Moves into Personalized Medicine
Abbott Gains Synchrony Accommodating IOL Via $400 Mil. Visiogen Purchase
Abbott Gains Synchrony Accommodating IOL Via $400 Mil. Visiogen Purchase
ArthroCare CEO Resigns As Inquiry Into Accounting, Billing Practices Expands
ArthroCare CEO Resigns As Inquiry Into Accounting, Billing Practices Expands

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel